INTRODUCTION -WHAT IS PCD?
Primary Ciliary Dyskinesia (PCD) refers to a varied group of genetic conditions caused by defective cilia function.
[1] The specific defect in function, clinical phenotype and inheritance varies between different mutations. Motile cilia line the respiratory tract, ventricles of the brain and fallopian tubes and are responsible for the motility of spermatozoa. Normal cilia ultrastructure consists of 2 microtubules surrounded by 9 microtubules, known as the "9 plus 2 arrangement". The outer microtubules have inner and outer dynein arms, which generate ciliary movement.
In PCD cilia may be immobile, dyskinetic or aplastic. [2] There are already over 30 different mutations known to result in PCD, which is predominantly inherited in an autosomal recessive fashion. In the fetus motile cilia present on the embryonic node are involved in left-right chest and abdominal organ arrangement. [1, 3] Situs inversus is found in about half of people with PCD. [2] Kartagener's syndrome is a triad of situs inversus, chronic sinusitis and bronchiectasis. Children with heterotaxic congenital heart disease, where there is isomerism of the atrial appendage and often other organ involevement as well, for example polysplenia or asplenia, should also be investigated for PCD. [4] The estimated prevalence of PCD is 1 in 10 000, however this is recognised to be much higher in certain populations. [5] For example, a study found a prevalence of 1 in 2265 in a British Asian population and of these patients around half had consanguineous parents. [6] It is important that clinicians are aware of features (see Table 1 ) that are suggestive of a potential diagnosis of PCD in order that children can be promptly referred for diagnostic testing. PICADAR (PrImary CiliARy DyskinesiA Rule) is a recently developed tool to help identify children that should be referred for testing (see Table 3 ). [7] Table 3 , possible scores range from 0 to 14, questions are based on birth and neonatal history and presence of situs abnormalities, congenital heart disease, perennial rhinitis and hearing or ear problems)
Adapted from Lucas et al. (2016) . [8] NO is produced by enzymatic action of nitric oxide synthetases and biologically is a key signalling molecule involved in multiple processes; most notably causing smooth muscle relaxation and vasodilatation. [12] It is important to make the distinction between nNO, which is often expressed in terms of flow as nL/minute, and fractional exhaled (whole breath) NO that is commonly used as a biomarker of eosinophilic inflammation in asthma and reported as a concentration in parts per billion. [13, 14] Several studies have identified significantly low levels of nNO in patients with PCD compared with healthy volunteers and other respiratory disease comparators, most notably cystic fibrosis. [15] [16] [17] [18] [19] [20] The exact mechanism by which nNO levels are low in PCD is currently unknown. [2, 19, 20] Divergent hypotheses have been proposed ranging from increased metabolism or reduced production of NO by airway epithelial cells in PCD to abnormalities in the paranasal sinuses leading to obstruction of NO or reduced production at this site. [20] nNO concentration is detected by sampling nasal gas. The "gold standard" method of measuring nNO concentration is by using a static chemiluminescence analyser.[1, 21] The patient is seated and a nasal sampling tube is placed into one nostril while air is entrained into the other nostril. The patient is then asked to hold their breath whilst performing a velum closure manoeuvre for 20 seconds. [21] Velum closure is when the patient exhales through their mouth against resistance. This ensures that the soft palate is closed and prevents any contamination from the pharynx. [21] The analyser displays nNO concentration in real time enabling a measurement from the peak plateau to be taken. A concentration in parts per billion is then converted to nL/minute to reflect the sampling rate. Medications the patient is taking are recorded, drugs such as nasal decongestents or steroids or antihistamines may alter nNO levels. [21] The sensitivity and specificity of nNO as a test for PCD varies between different studies depending on the method of sampling, analyser used and age of the individual patients. [8, 19] There is no universally agreed diagnostic threshold although 77nL/minute is most commonly used for children of school age and above using the velum closure technique. [19] The 2016 ERS guidelines conclude that sensitivity and specificity for diagnosing PCD by static chemiluminescence analyser measurements using velum closure technique in children over 6 years are favourable, at between 0.9-1 and 0.75-0.97 respectively. [8] Stationary chemiluminescent analysers are expensive and best suited to large tertiary centres. Portable electrochemical devices have also been developed, which are cheaper and easier to use. There is limited data comparing stationary and portable nNO devices but studies have shown them to be reliable in assessing nNO levels. [22, 23] Portable devices require the patient to hold their breath for longer and do not display the sampling in real time preventing sampling acceptability to be measured.
DIAGNOSIS OF PCD
An important further caveat is that in children under 6 years nNO measurement is particularly challenging and furthermore differences between children with PCD and healthy controls are less marked in the youngest age groups. [24] Pre-school children often struggle to perform velum closure manoeuvres therefore tidal breathing measurements have to be used that are less well validated and appear to be less accurate. [25] CLINICAL BOTTOM LINE The ERS guidelines also suggest use of a recently developed predictive tool, PICADAR, see Table 3 . [7, 8] This uses seven simple questions to predict the likelihood of a child having PCD. A score greater than 5 is considered significant, and has a sensitivity of 0.9 and specificity of 0.75, that should prompt referral for testing. nNO should only be considered a screening test for PCD. Given the clinical history the pretest probability of PCD is high, the child has a PICADAR score of 6, and therefore they have been appropriately screened and a diagnosis of PCD is highly likely. The nNO test does however, have limitations. Low nNO levels can also occur in cystic fibrosis, sinusitis, nasal polyps, nasal obstruction and during an acute respiratory tract infection.
[1] Further testing, for example HSVA, is also indicated for a definitive diagnosis of PCD to be reached. [8] Conversely it is also worth noting that there have been rare cases of PCD reported where nNO levels are within the normal range, for example some people with PCD associated with RSPH1 mutations have been found to have nNO levels >77 nL/min. [26] Therefore false negative results are also possible. This reiterates that if nNO levels are normal despite a classical history, referral for diagnostic testing is warranted. [2] Collins et al. published model predictive values for nNO levels using 282 consecutive referrals to their PCD service. [27] Using a screening threshold of 77 nL/min to exclude PCD they found that their data produced a sensitivity of 93.6% (95% CI 78.6-99.2) and specificity of 84.1% (78.9-88.4) with a positive predictive value of 42% (30.2 -54.5) and negative predictive value of 99.1% (96.7 to 99.9). [27] This suggests that a screening threshold of 77 nL/min is generally effective in excluding PCD (whilst being mindful of the aforementioned caveat of potential false negative results) but that targeted screening of children with a raised pre-test probability based on their clinical history is likely to be most useful and effective in order to avoid overwhelming specialist services with children with false positive screening results in the absence of classical symptoms. [27] In summary therefore the history and screening test in this clinical scenario is suggestive of PCD and the patient requires prompt referral to a tertiary paediatric respiratory service for diagnostic testing. 
